Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
Clinical trial NCT05392257 · UNKNOWN
Trial details
- NCT number
- NCT05392257
- Sponsor
- Qingdao Central Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2024-05-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.